Investigating prescribers' experiences of direct-acting oral anticoagulants for the management of nonvalvular atrial fibrillation

Daria Generalova
Direct-acting oral anticoagulants (DOACs) have relatively recently been licensed for stroke and systemic embolism prevention in patients with non-valvular atrial fibrillation (AF) and have replaced warfarin as the first line agent of choice. The aim of this research was to determine prescribers' views and experiences of the use of DOACs for the management of non-valvular AF. The first phase was a PROSPERO-registered systematic review of clinicians' views and experiences of DOACs for the management of...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.